Overall rank by patents
#43,754
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Tune Therapeutics, Inc.
USPTO PatentsView assignee record - 6 granted patents across 3 technology areas, active 2024–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
6
Total patents granted
3
CPC technology areas
24.8
Avg claims per patent
-
5-year filing velocity
The verdict
Tune holds 6 US patents across 3 technology areas, rank #43,754 of 50,000 tracked assignees.
- #43,754
- of 50,000 US assignees by volume
- Top 52%
- by Innovation Score (34.4/100)
- 24.8
- avg claims per patent
Portfolio overview
Tune Therapeutics, Inc. has been granted 6 US utility patents between 2024 and 2025, placing Tune Therapeutics, Inc. at rank #43,754 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 24.8 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Tune Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Tune sits between Truckpay Inc. (6 patents, rank #43,750) and Turbodynamics Gmbh (6 patents, rank #43,758) - the closest US assignees by grant volume. The composite Innovation Score of 34.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2024 through 2025, with 6 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Tune Therapeutics, Inc.'s 24.8 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Tune Therapeutics, Inc. against peers pursuing similar technology classes.
Who files at Tune's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Truckpay
TruckPay Inc.
6 patents
- True Organic Prod…
True Organic Products, Inc.
6 patents
- Trunomi
Trunomi Ltd.
6 patents
- Tuboscope Vetco (…
Tuboscope Vetco (France) SAS
6 patents
- Turbine Powered T…
Turbine Powered Technology, LLC
6 patents
- Turbineone
TurbineOne, Inc.
6 patents
- Turbochef
TurboChef Technologies, LLC
6 patents
- Turbodynamics
Turbodynamics GmbH
6 patents
- Tune Therapeutics ◀
Tune Therapeutics, Inc.
6 patents
What this shows Tune holds 6 patents at rank #43,754, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Tune
By rank, the assignees closest to #43,754 in granted patent volume.
- Truckpay Inc. #43,750 · 6 patents
- True Organic Products, Inc. #43,751 · 6 patents
- Trunomi Ltd. #43,752 · 6 patents
- Tuboscope Vetco (france) SAS #43,753 · 6 patents
- Turbine Powered Technology, Llc #43,755 · 6 patents
- Turbineone, Inc. #43,756 · 6 patents
- Turbochef Technologies, Llc #43,757 · 6 patents
- Turbodynamics Gmbh #43,758 · 6 patents
Leaders in C12N (Microorganisms OR Enzymes)
Other assignees with the most granted patents in Tune's primary technology class.
- Monsanto Technology Llc 1,335 in class
- The Regents Of The University Of California 1,161 in class
- Novozymes A/s 656 in class
- Immatics Biotechnologies Gmbh 647 in class
- Pioneer Hi-bred International, Inc. 623 in class
- President And Fellows Of Harvard College 594 in class
- Massachusetts Institute Of Technology 541 in class
- The Trustees Of The University Of Pennsylvania 537 in class
Tune's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
34 Top 52% higher than 48% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2024–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2024 | 1 | 16.7% |
| 2025 | 5 | 83.3% |
Which technologies does Tune Therapeutics, Inc. patent most?
Top 3 of 3 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex
Frequently Asked Questions
How many patents does Tune Therapeutics, Inc. hold?
Tune Therapeutics, Inc. holds 6 US granted patents filed between 2024 and 2025, spanning 3 technology areas.
What is Tune Therapeutics, Inc.'s Innovation Score?
Tune Therapeutics, Inc. has an Innovation Score of 34.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Tune Therapeutics, Inc. focus on?
Tune Therapeutics, Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 6 patents. The company has filed patents in 3 CPC subclasses total.
Is Tune Therapeutics, Inc.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Tune Therapeutics, Inc..
What does claim depth mean for Tune Therapeutics, Inc.'s patents?
Tune Therapeutics, Inc.'s patents average 24.8 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Tune Therapeutics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Tune's 6 grants land it in the top 52% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Tune ranks #43,754 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.